RXST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RxSight Inc (RXST) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has bearish technical indicators, and recent financial performance shows declining revenue. While there are some improvements in net income and gross margin, the overall sentiment remains neutral to slightly negative. It is better to wait for stronger signals or evidence of a turnaround before investing.
The MACD histogram is slightly positive at 0.000712, indicating weak bullish momentum. RSI is neutral at 44.175, showing no clear overbought or oversold conditions. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and the stock is trading below its pivot level of 7.51. Key support levels are at 7.031 and 6.734, while resistance levels are at 7.989 and 8.286.
The stock has a 19.26% chance to rise in the next month based on candlestick pattern analysis.
Analysts have lowered price targets recently, with most maintaining Neutral or Hold ratings. No significant hedge fund or insider trading activity. No recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue declined by 18.91% YoY to $32.61M. However, net income improved to -$9.15M (+54.13% YoY), and EPS increased to -0.22 (+46.67% YoY). Gross margin improved to 77.47% (+8.21% YoY). Despite some improvements in profitability metrics, the overall financial performance remains weak due to declining revenue.
Analysts have a Neutral sentiment overall. Recent price target changes include Stifel lowering the target to $9 from $10, UBS raising it to $9 from $8, and Piper Sandler lowering it to $10 from $11. Analysts highlight concerns about stalled sales growth and a lower 2026 outlook, limiting downside risk but not providing strong upside potential.
